Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 18/20 | 0.74 |
| ▸ | EDNRB | P24530 | 7/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | DHPS | P49366 | 1/20 | 0.65 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.65 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840430 | 1.00 | EDNRA (0.74) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Potassium SCHEMBL7842390 | 0.99 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7831360 | 0.99 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7843011 | 0.96 | EDNRA (0.68) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7843008 | 0.96 | EDNRA (0.68) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7839347 | 0.93 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7839344 | 0.93 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7838729 | 0.92 | EDNRA (0.65) | EDNRAEDNRB | |
| SCHEMBL7838730 | 0.92 | EDNRA (0.65) | EDNRAEDNRB | |
| SCHEMBL7844451 | 0.92 | EDNRA (0.64) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882719-B1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2001-05-16 | — | — | EP | claimed |
| US-6083955-A | HAVING A HIGH AFFINITY FOR DRUGS, ESPECIALLY ENDOSERINE RECEPTORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | claimed |
| EP-0882719-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | DONEHEW FUND LIMITED PARTNERSHIP | 2008-10-23 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0882719-B1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-6083955-A | HAVING A HIGH AFFINITY FOR DRUGS, ESPECIALLY ENDOSERINE RECEPTORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0882719-A1 | ARYLETHENESULFONAMIDE DERIVATIVES AND DRUG COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885ABCC3 1458/4885 |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | EDNRB, EDNRA, ECE1 | EDNRA 2/4885EDNRB 1/4885ABCC3 3101/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | EDNRA 11/4885EDNRB 8/4885ABCC3 3922/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885ABCC3 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.